Docsun Biomed Report on Omicron Variant in the United States

By: CDC
 
JHUBEI CITY, Taiwan - Jan. 10, 2022 - PRLog -- Since identifying the first case of the Omicron variant in the United States on December 1, 2021, CDC has been working with state, tribal, local, and territorial public health officials to monitor the spread of Omicron in the United States. On December 10, 2021, CDC released an MMWR article summarizing characteristics of the first Omicron infections in the country. CDC has also identified a rapid increase in infections consistent with what has been observed in other countries. Increases in infections are most likely due to a combination of two factors: increased transmissibility and immune evasion (the ability of the variant to evade immunity conferred by past infection or vaccination). Though the precise contribution of each of the two factors remains unknown, a substantial degree of immune evasion is likely as has been demonstrated in early in vitro studies.

The clinical severity profile of Omicron infection will strongly influence its impact on U.S. hospitalizations and deaths. A study from South Africaexternal icon demonstrates that in the first four weeks of the Omicron variant wave there were lower rates of hospitalization compared to the first four weeks of the Beta- or Delta-dominated waves in Gauteng Province. There was also less severe illness reported for those that were admitted. A study conducted in Canadaexternal icon found that the risk of hospitalization was 54% lower for Omicron cases compared with Delta cases.

Some studies have demonstrated the importance of booster doses in protecting against infection with Omicron, and a lower effectiveness of the primary series of vaccines alone. Current CDC recommendations for vaccines and booster shots are expected to protect against severe illness, hospitalizations, and deaths from infection with the Omicron variant. Therapeutics, including monoclonal antibody treatments and antivirals, are also available for preventing and treating COVID-19 in specific at-risk populations.

Scientists around the world, including researchers at CDC, are working quickly to learn more about the Omicron variant. The recent emergence of Omicron and the fact that Delta is still a circulating variant further emphasize the importance of getting a primary vaccination series and, if eligible, a booster and continuing prevention measures.

DocSun∙Computation∙MedLab∙Ltd (https://docsun.health/)∙mission∙is∙using∙technology∙to∙create∙life-long∙ Solutions∙ ∙∙∙The ∙article∙reference∙data∙from∙the∙CDC∙

Original links to the article: - https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html

Contact
Docsun Computation Medlab Ltd
***@docsun.health
End
Email:***@docsun.health Email Verified
Tags:COVID-19
Industry:Health
Location:Jhubei City - Hsinchu - Taiwan
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Docsun Computation Medlab Ltd PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share